AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19955857 — intervention group
Group type: EXPERIMENTAL
Intervention: AF patients with persistent LAT
Number of subjects: 226
Study 16765701 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual small-incision cataract surgery (MSICS)
Number of subjects: 150
Study 16765701 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification (PE)
Number of subjects: 150
Study 14706957 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 540) received individualized counseling about modifying fat quality and quantity in diet.
Number of subjects: 1062
Study 14706957 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 522) did not receive the same dietary counseling.
Number of subjects: 1062
Study 14706957 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 540)
Number of subjects: 1062
Study 14706957 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 522)
Number of subjects: 1062
Study 14706957 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1062
Study 11715663 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential phospholipids (EPL) administered intravenously, 50 mg every 6 hours for 2 weeks
Number of subjects: 20
Study 11715663 — intervention group
Group type: COMPARATOR
Intervention: Control group without hepatoprotection
Number of subjects: 20
Study 9383499 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (1 mg tablets/2 mg oral dose)
Number of subjects: 9
Study 9383499 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg tablets/8 mg oral dose)
Number of subjects: 9
Study 9383499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8042069 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course treatment
Number of subjects: 100
Study 8042069 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 100
Study 3392240 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 400 mg once daily
Number of subjects: 11
Study 3392240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31366980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 31366980 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ascorbic acid
Number of subjects: 93
Study 31366980 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg ascorbic acid
Number of subjects: 93
Study 28288172 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (mRDTs training and provision of mRDTs and AL)
Number of subjects: 1400
Study 28288172 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1400
Study 25002367 — intervention group
Group type: EXPERIMENTAL
Intervention: Startling acoustic stimulus
Number of subjects: 8
Study 25002367 — intervention group
Group type: COMPARATOR
Intervention: Non-startling acoustic stimuli (get ready and go)
Number of subjects: 8
Study 23338056 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block with 0.25% levobupivacaine 0.5 ml kg(‐1)
Number of subjects: 57
Study 23338056 — intervention group
Group type: COMPARATOR
Intervention: Wound infiltration with 0.2 ml kg(‐1) 0.25% levobupivacaine
Number of subjects: 57
Study 21192750 — intervention group
Group type: EXPERIMENTAL
Intervention: Get Moving Web site intervention
Number of subjects: 221
Study 21192750 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 221
Study 19320980 — intervention group
Group type: EXPERIMENTAL
Intervention: Best Start intervention
Number of subjects: 1666
Study 19320980 — intervention group
Group type: COMPARATOR
Intervention: Control (rest of the state)
Number of subjects: 1666
Study 18386621 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryonary peptides (EP) administered for 60 days
Number of subjects: 0
Study 18386621 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryonary peptides (EP)
Number of subjects: 0
Study 12553951 — intervention group
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid enriched 20% lipid emulsion (MCT:LCT:fish oil = 5:4:1, MLF541; Lipoplus) for 5 days postoperatively
Number of subjects: 30
Study 12553951 — intervention group
Group type: COMPARATOR
Intervention: standard 20% fat emulsion (LCT; Intralipid)
Number of subjects: 30
Study 10714908 — intervention group
Group type: EXPERIMENTAL
Intervention: E2-DSG (1.5 mg E2 for 24 days with 0.15 mg DSG for the last 12 days followed by a placebo tablet for 4 days)
Number of subjects: 376
Study 10714908 — intervention group
Group type: COMPARATOR
Intervention: E2V-MPA (2 mg E2V for 21 days with 10 mg MPA for the last 10 days)
Number of subjects: 376
Study 10714908 — intervention group
Group type: EXPERIMENTAL
Intervention: E2-DSG
Number of subjects: 376
Study 10714908 — intervention group
Group type: COMPARATOR
Intervention: E2V-MPA
Number of subjects: 376
Study 10714908 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 376
Study 9361328 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 2 mg
Number of subjects: 15
Study 9361328 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 4 mg
Number of subjects: 15
Study 9361328 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 6 mg
Number of subjects: 15
Study 9361328 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2.5 mg
Number of subjects: 15
Study 9361328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1549940 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-fentanyl
Number of subjects: 44
Study 1549940 — intervention group
Group type: COMPARATOR
Intervention: Thiopental-halothane
Number of subjects: 44
Study 6532148 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem solving training
Number of subjects: 33
Study 6532148 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo control
Number of subjects: 33
Study 6532148 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping with guilt and personal failure training
Number of subjects: 33
Study 31343391 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin combined with Daptomycin
Number of subjects: 30
Study 30340490 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based mechanisms (Mothers committees, Jaanch committees, Village Health and Sanitation Committees, Self-Help Groups)
Number of subjects: 84
Study 30340490 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Help Groups
Number of subjects: 84
Study 27829030 — intervention group
Group type: EXPERIMENTAL
Intervention: Point fixation target
Number of subjects: 29
Study 27829030 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross fixation target
Number of subjects: 29
Study 27829030 — intervention group
Group type: EXPERIMENTAL
Intervention: Ring fixation target
Number of subjects: 29
Study 24883319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine + Tramadol (50 mg)
Number of subjects: 36
Study 24883319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine + Ketamine (50 mg)
Number of subjects: 36
Study 24883319 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine (Control)
Number of subjects: 36
Study 21042930 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Strengths Model bridging case management intervention (BCM)
Number of subjects: 104
Study 21042930 — intervention group
Group type: COMPARATOR
Intervention: Standard of care prison-administered discharge planning program (SOC)
Number of subjects: 104
Study 20071289 — intervention group
Group type: EXPERIMENTAL
Intervention: CIPRO XR 1000 mg once daily
Number of subjects: 212
Study 20071289 — intervention group
Group type: COMPARATOR
Intervention: CIPRO IR 500 mg twice daily
Number of subjects: 212
Study 16459272 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.1 mg/kg IV over 2 min) + Naloxone (0.1 ng/kg)
Number of subjects: 156
Study 16459272 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.1 mg/kg IV over 2 min) + Naloxone (0.01 ng/kg)
Number of subjects: 156
Study 16459272 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.1 mg/kg IV over 2 min) + Naloxone (0.001 ng/kg)
Number of subjects: 156
Study 16459272 — intervention group
Group type: COMPARATOR
Intervention: Morphine (0.1 mg/kg IV over 2 min) + Normal Saline (Control)
Number of subjects: 156
Study 15297901 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 300 mg/day WS 5570
Number of subjects: 425
Study 15297901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 425
Study 11345689 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicis cortex extract with 240 mg salicin/day
Number of subjects: 51
Study 11345689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 11345689 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylate 100 mg/day
Number of subjects: 51
Study 9215540 — intervention group
Group type: EXPERIMENTAL
Intervention: Legume consumption (120 gm mixed legumes substituted for foods with equivalent calories, fat, protein, and carbohydrate)
Number of subjects: 9
Study 9215540 — intervention group
Group type: EXPERIMENTAL
Intervention: Legume consumption
Number of subjects: 9
Study 9215540 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 9
Study 8025207 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide plus intensive insulin treatment (Group B)
Number of subjects: 27
Study 8025207 — intervention group
Group type: COMPARATOR
Intervention: Intensive insulin treatment alone (Group A)
Number of subjects: 27
Study 8025207 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (overall)
Number of subjects: 27
Study 8025207 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (C-peptide levels)
Number of subjects: 27
Study 8025207 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not entering remission (C-peptide levels)
Number of subjects: 27
Study 3631495 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (5-7.5 mg)
Number of subjects: 60
Study 3631495 — intervention group
Group type: COMPARATOR
Intervention: Meperidine (50-75 mg) and Promethazine (25-50 mg)
Number of subjects: 60
Study 67338 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine, 900 mg daily
Number of subjects: 27
Study 67338 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine (for 4 patients over a year)
Number of subjects: 27
Study 67338 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 7 patients with serial liver-copper measurements)
Number of subjects: 27
Study 67338 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine
Number of subjects: 27
Study 31802733 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide treatment (CWT)
Number of subjects: 150
Study 31802733 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based treatment (SBT)
Number of subjects: 150
Study 31802733 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined arms of villages that received four rounds of treatment
Number of subjects: 150
Study 31802733 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based treatment (SBT) for first-year primary students and adults
Number of subjects: 150
Study 31684847 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) under level 1A evidence
Number of subjects: 0
Study 31684847 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) under level 2B evidence
Number of subjects: 0
Study 31684847 — intervention group
Group type: COMPARATOR
Intervention: No EVT offered under level 1A evidence
Number of subjects: 0
Study 27761633 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic lithotripters (group-1)
Number of subjects: 267
Study 27761633 — intervention group
Group type: EXPERIMENTAL
Intervention: Ho:YAG laser lithotripters (group-2)
Number of subjects: 267
Study 26720025 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus triptorelin (LHRHa group)
Number of subjects: 281
Study 26720025 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (control group)
Number of subjects: 281
Study 22936210 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee model with skin holes left by peers
Number of subjects: 60
Study 22936210 — intervention group
Group type: COMPARATOR
Intervention: Knee model with no marks in the skin (control)
Number of subjects: 60
Study 21188413 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest tertile of skin autofluorescence (AF)
Number of subjects: 232
Study 21188413 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle tertile of skin autofluorescence (AF)
Number of subjects: 232
Study 21188413 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of skin autofluorescence (AF)
Number of subjects: 232
Study 19737046 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperhydration
Number of subjects: 8
Study 19737046 — intervention group
Group type: EXPERIMENTAL
Intervention: Euhydration
Number of subjects: 8
Study 19737046 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypohydration
Number of subjects: 8
Study 17253878 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AEDs) with serotonergic properties (e.g., carbamazepine, oxcarbazepine, valproate, lamotrigine)
Number of subjects: 0
Study 17253878 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital and phenytoin
Number of subjects: 0
Study 17253878 — intervention group
Group type: EXPERIMENTAL
Intervention: Other AEDs (e.g., topiramate, tiagabine, vigabatrin, levetiracetam, zonisamide)
Number of subjects: 0
Study 17253878 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study 14999565 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution magic angle spinning (HR MAS) MR spectroscopy
Number of subjects: 16
Study 11573114 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200mg single dose followed by 100mg daily for 6 days)
Number of subjects: 280
Study 11573114 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadoxine/Pyrimethamine (1500mg sulphadoxine and 75mg pyrimethamine as a single dose)
Number of subjects: 280
Study 11573114 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of Sulphadoxine/Pyrimethamine and Doxycycline
Number of subjects: 280
Study 11573114 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 280
Study 9042046 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (20 mg/m2 body area)
Number of subjects: 15
Study 9042046 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (20 mg)
Number of subjects: 15
Study 9042046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7949107 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB-irradiated pooled platelets
Number of subjects: 101
Study 7949107 — intervention group
Group type: COMPARATOR
Intervention: Standard pooled platelets (control group)
Number of subjects: 101
Study 3239618 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital fluid pressure monitor
Number of subjects: 8
Study 3239618 — intervention group
Group type: COMPARATOR
Intervention: Needle manometer technique
Number of subjects: 8
Study 30352668 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Dual Diagnosis Treatment (IDDT)
Number of subjects: 154
Study 30352668 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 154
Study 30352668 — intervention group
Group type: EXPERIMENTAL
Intervention: IDDT training for clinicians
Number of subjects: 154
Study 28441974 — intervention group
Group type: EXPERIMENTAL
Intervention: PM+ Group intervention (5 sessions, 3 hours each)
Number of subjects: 612
Study 28441974 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no specific intervention mentioned)
Number of subjects: 612
Study 28441974 — intervention group
Group type: EXPERIMENTAL
Intervention: PM+ Group intervention
Number of subjects: 612
Study 26025097 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection (IAI) 2 mg every 4 weeks (2q4)
Number of subjects: 2457
Study 26025097 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection (IAI) 2 mg every 8 weeks (after 3 monthly doses; 2q8)
Number of subjects: 2457
Study 26025097 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection (IAI) 0.5 mg every 4 weeks (0.5q4)
Number of subjects: 2457
Study 26025097 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab 0.5 mg every 4 weeks (Rq4)
Number of subjects: 2457
Study 26025097 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection (IAI) 2 mg every 8 weeks (2q8)
Number of subjects: 2457
Study 24135273 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased knee joint loading (Loaders)
Number of subjects: 157
Study 24135273 — intervention group
Group type: COMPARATOR
Intervention: Reduced knee joint loading (Unloaders)
Number of subjects: 157
Study 21263078 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Insomnia (BBTI)
Number of subjects: 79
Study 21263078 — intervention group
Group type: COMPARATOR
Intervention: Information Control (IC)
Number of subjects: 79
Study 19055281 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming needle therapy
Number of subjects: 117
Study 19055281 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 117
Study 19055281 — intervention group
Group type: COMPARATOR
Intervention: Medication (Salicylazosulfapyridine and Azathiopurine)
Number of subjects: 117
Study 16735709 — intervention group
Group type: EXPERIMENTAL
Intervention: RT with concomitant TMZ followed by adjuvant TMZ
Number of subjects: 573
Study 16735709 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 573
Study 14739418 — intervention group
Group type: EXPERIMENTAL
Intervention: Aphasia therapy
Number of subjects: 3
Study 14739418 — intervention group
Group type: COMPARATOR
Intervention: Controls (N=3)
Number of subjects: 3
Study 11710652 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-set strength training (1 set of 6-9 repetitions until failure)
Number of subjects: 27
Study 11710652 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-set strength training (3 sets of 6-9 repetitions until failure, rest interval 2 minutes)
Number of subjects: 27
Study 11710652 — intervention group
Group type: COMPARATOR
Intervention: Nontraining control group
Number of subjects: 27
Study 9401993 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional ultrasonography
Number of subjects: 18
Study 9401993 — intervention group
Group type: COMPARATOR
Intervention: Two-dimensional ultrasonography
Number of subjects: 18
Study 9401993 — intervention group
Group type: COMPARATOR
Intervention: Conventional prediction methods
Number of subjects: 18
Study 9401993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal volume parameters
Number of subjects: 18
Study 8273399 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone-L-carnitine combination (4 g/5 days of L-carnitine and 2 mg/1 day of betamethasone)
Number of subjects: 109
Study 8273399 — intervention group
Group type: COMPARATOR
Intervention: High dose betamethasone (8 mg/2 days)
Number of subjects: 109
Study 3034062 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (25, 50, 100, or 200 micrograms/day)
Number of subjects: 50
Study 3034062 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estradiol (50 micrograms patch)
Number of subjects: 50
Study 3034062 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estradiol (100 micrograms patch)
Number of subjects: 50
Study 3034062 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (all doses)
Number of subjects: 50
Study 3034062 — intervention group
Group type: COMPARATOR
Intervention: Conjugated equine estrogen (0.625 mg and 1.25 mg)
Number of subjects: 50
Study 31326308 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadoxetic Acid enhanced MRI
Number of subjects: 20
Study 29697993 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory training combined with recollection training based on the repetition‐lag procedure
Number of subjects: 36
Study 29697993 — intervention group
Group type: COMPARATOR
Intervention: Standard memory training (active control group)
Number of subjects: 36
Study 26690370 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mail messages
Number of subjects: 848
Study 26690370 — intervention group
Group type: EXPERIMENTAL
Intervention: Fax messages
Number of subjects: 848
Study 26690370 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS messages
Number of subjects: 848
Study 26690370 — intervention group
Group type: COMPARATOR
Intervention: No-message control group
Number of subjects: 848
Study 24750838 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg/(m(2)·d), Qd) for 6 months
Number of subjects: 20
Study 24750838 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 20
Study 23803270 — intervention group
Group type: COMPARATOR
Intervention: Manual lymphatic drainage (MLD) for 40 minutes
Number of subjects: 46
Study 23803270 — intervention group
Group type: COMPARATOR
Intervention: Low-level laser therapy (LLLT) for 20 minutes
Number of subjects: 46
Study 23803270 — intervention group
Group type: COMPARATOR
Intervention: 20 minutes of MLD followed by 20 minutes of LLLT
Number of subjects: 46
Study 23803270 — intervention group
Group type: EXPERIMENTAL
Intervention: LLLT with bandaging
Number of subjects: 46
Study 23803270 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression bandaging alone
Number of subjects: 46
Study 19827012 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted logrank (WLR) test
Number of subjects: 0
Study 19827012 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted Kaplan-Meier (WKM) test
Number of subjects: 0
Study 19827012 — intervention group
Group type: EXPERIMENTAL
Intervention: Versatile tests combining WLR and WKM
Number of subjects: 0
Study 19133098 — intervention group
Group type: EXPERIMENTAL
Intervention: Mtwo
Number of subjects: 90
Study 19133098 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper
Number of subjects: 90
Study 19133098 — intervention group
Group type: COMPARATOR
Intervention: NiTi-hand files
Number of subjects: 90
Study 16550737 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg) from Laboratórios Cristália Ltd.
Number of subjects: 25
Study 16550737 — intervention group
Group type: COMPARATOR
Intervention: Cozaar (50 mg) from Merck Sharp & Dohme Farmacêutica Ltd.
Number of subjects: 25